bluuebunny/crossref_metadata_2025 huggingface dataset:
Fully automated measurements of echocardiographic mechanical dispersion using deep learning: enhanced prediction of ventricular arrhythmias in a large heart failure cohort
Authors: Melichova D , Nyberg J , Nguyen T M , Salte I M , Brunvand H , Haugaa K , Edvardsen T , Dalen H , Lovstakken L , Ostvik A , Grenne B
Published: October 2024

Background

Assessment of left ventricular (LV) myocardial deformation by strain echocardiography has shown improved prognostic value over LV ejection fraction (LVEF). Mechanical dispersion (MD) by strain reflects deformation heterogeneity. Also, MD is a marker of ventricular arrhythmia (VA) that improves risk prediction independently of LVEF in patients with heart failure. However, to analyze MD is time consuming and operator-dependent, and clinical use remains limited.

Purpose

We aimed to investigate the performance of a novel deep learning (DL) based method for fully automated measurements of MD and evaluate its prognostic utility in patients with heart failure compared to a conventional speckle tracking application.

Methods

In this prospective multicenter follow up study, the IMPROVE study, we consecutively included patients with recently diagnosed heart failure of all cause with LVEF ≤ 40%. Echocardiograms, ECG, blood samples and clinical data were acquired during index hospitalization. All patients were treated according to contemporary guidelines with optimal medical therapy and revascularization if necessary. Two experienced cardiologists recorded all echocardiograms using Vivid E9 or E95 scanners. We obtained data regarding sudden cardiac death, ventricular arrhythmia and appropriate shock from the ICD from medical records and ICD recordings. The primary endpoint was sudden cardiac death or ventricular arrhythmia (SCD/VA) during follow-up. The prognostic value of DL-based and reference MD measurements was assessed through survival statistics.

Results

We included 492 patients (mean ± SD 73 ± 13 years old, 32% females). Follow-up time was median (IQR) 5 (3) years. The incidence of SCD/VA was 9% (n=45). Patients with MD ≥70ms had increased risk of SCD/VA both by DL-based and reference measurements (both p <0.001). Furthermore, automated MD measurements using DL had higher prognostic value (HR 4.3) compared to manual reference measurements (HR 3.1) (p <0.001).

Conclusion

Fully automated measurements of MD using a novel DL method was fast, feasible, and improved prediction of SCD/VA in patients with heart failure and reduced LVEF. The integration of DL measurements may facilitate the clinical implementation of MD assessment and improve risk prediction in echocardiography.
Serial changes in left atrial strain in symptomatic obstructive hypertrophic cardiomyopathy treated with mavacamten: insights from VALOR-HCM trial
Authors: Desai M , Okushi Y , Popovic Z , Wolski K , Owens A , Geske J , Saberi S , Wang A , Cremer P , Lakdawala N , Tower-Rader A , Fermin D , Naidu S , Lampl K , Sehnert A
Published: October 2024

Background

In severely symptomatic patients with obstructive hypertrophic cardiomyopathy (HCM), the VALOR-HCM phase 3 randomized, double-blind, placebo-controlled clinical trial demonstrated that mavacamten, a cardiac myosin inhibitor, reduces the eligibility for septal reduction therapy with sustained improvement in left ventricular (LV) outflow tract gradients and symptoms. Mavacamten also resulted in favorable cardiac remodeling, including improvement in left atrial volume index (LAVI), LV diastolic function, and biomarkers (NT-proBNP and troponin T). However, the impact of mavacamten on LA function is not known.

Objective

We sought to assess serial changes in LA strain measures in patients enrolled in the VALOR-HCM trial.

Methods

VALOR-HCM included 112 symptomatic obstructive HCM patients (mean age 60 years, 51% male). Patients assigned to mavacamten at baseline (n=56) continued therapy for 56 weeks and those assigned to placebo crossed over to mavacamten (n=52) from week 16-56 (40-week exposure). Echocardiographic LA strain assessment was performed according to the current American and European guideline recommendations, using a vendor-neutral post processing software. For assessment of LA strain components (reservoir, conduit, and contraction), the non-foreshortened apical 4-chamber view was utilized. The zero reference was set at end-diastole.

Results

Serial changes in LAVI and all components of mean LA strain from baseline to week 56 are shown in the Figure. At baseline, LAVI and all mean LA strain values were worse than reported normal mean thresholds. There was a continued and significant improvement in all 3 LA strain values, from baseline to week 56, along with a significant reduction in LAVI. Improvement in LAVI was seen earlier than improvements in LA strain. There was a significant inverse correlation between change in mean LAVI and LA reservoir strain from baseline to week 56 (r= -0.42, p<0.001).

Conclusions

In the VALOR-HCM trial, average LAVI and baseline LA strain values were significantly worse than reported normal thresholds. Treatment with mavacamten resulted in an improvement in LAVI and LA strain values from baseline through week 56 suggesting a sustained favorable impact on cardiac remodeling. The advantageous cardiac remodeling associated with long-term treatment with mavacamten may in turn have a favorable impact on the observed high burden of atrial tachyarrhythmias in HCM.Serial changes in LA strain in VALOR-HCM
Atrial cardiomyopathy in postmenopausal female healthcare professionals- a single-center study
Authors: Borizanova-Petkova A , Kinova E , Goudev A
Published: October 2024

Background

Atrial cardiomyopathy (ACM) is a new clinical entity with significant importance, because of its potential to be a determinant of heart failure, atrial fibrillation and thromboembolic complications¹. Defining different atrial phenotypes is challenging, because of the lack of consensus for the diagnosis of ACM²'³. Menopausal transition is associated with adverse changes in women’s health such as obesity and hypertension, both known risk factors for ACM⁴.

Aim

To investigate left atrial (LA) structural and functional echocardiographic parameters in postmenopausal female healthcare professionals and to define atrial phenotype in this population.

Methods

Consecutive asymptomatic, postmenopausal, middle-age women (n=105), healthcare professionals from our hospital, were separated in 3 groups according to co-morbidities : with obesity (n=50), obesity and hypertension (n=24), healthy control (n=31). All patients underwent 2D echocardiographic examination with volumetric and speckle tracking analysis of LA.

Results

There were significant differences in LA structural and functional indices between 3 groups- table 1. Higher body mass index was associated with increased LA volume index (p<0.001, r= 0.56), reduced LA total emptying fraction- LATEF (p<0.001, r= -0.62), Peak atrial longitudinal strain-PALS (p<0.001, r= -0.59 ) and Peak atrial contractile strain- PACS (p<0.001, r= 0.56 ). ROC analysis was performed for identifying atrial phenotype of obese women with hypertension: LAVi 16.5ml/m2,(sensitivity 0.833, specificity 0.839, AUC 0.875), PALS 46.55% (sensitivity 0.903, specificity 0.875, AUC 0.951), PACS -20.75% (sensitivity 0.806, specificity 0.708, AUC 0.855), LATEF 69% (sensitivity 0.903, specificity 0.792, AUC 0.920)- figure 1.

Conclusion

Postmenopausal women with obesity and hypertension are at risk for asymptomatic ACM. Further investigations are needed to confirm this concept.
Comparison of left atrial and left atrial appendage mechanics in patients with ischaemic strokes of different aetiologies
Authors: Mao Y K , Yang Y , Ma M M , Yu C , Wang Y , Jiang R H , Jiang C Y
Published: October 2024

Background

Left atrial (LA) and left atrial appendage (LAA) mechanical dysfunction account for an increase in cardioembolic stroke risk in atrial fibrillation (AF), and more recently in individuals in sinus rhythm (SR). However, the exact contribution of LA and LAA to the pathogenesis of thromboembolic events is not fully understood. Here, we aimed to assess the alterations of LA and LAA mechanics in different stroke subtypes.

Methods

We recruited three groups of participants: patients with paroxysmal or persistent AF with a history of stroke (AF-stroke, n=69,respectively), individuals in SR with no history of AF but with acute ischaemic stroke(non-AF stroke,n=46); individuals with no history of AF or stroke(control group,n=17). Patients with AF were further categorized into sinus rhythm group (AF-stroke-SR,n=24) and AF rhythm group(AF-stroke-AF, n=45) according to the rhythm at the time of echocardiography. Using speckle-tracking echocardiography, global longitudinal strain (GLS) and mechanical dispersion (MD) of LA and LAA were measured in all patients. Mechanical dispersion was defined as the standard deviation of the time to peak of the regional strain corrected by R-R interval.

Results

Patients with AF-stroke demonstrated prominently impaired LA and LAA mechanics(LA GLS: 20±6%(AF-stroke-SR),11±4%(AF-stroke-AF); LA MD: 9±3%,11±3%; LAA GLS: 15±3%,11±4% ; LAA MD: 11±4%,12±3% ,respectively) compare with those with non-AF stroke and controls (LA GLS:35±8%, 41±11%;LA MD,6±2%, 4±2%; LAA GLS:21±5%, 23±7%; LAA MD:8±4%, 7±3%,respectively) (all p<0.01). Interestingly, LA and LAA mechanical function was not significantly different between patients with non-AF strokes and the control group. In multivariable analysis, only AF-strokes were independently associated with LA and LAA GLS after adjusting for age and comorbidities (both P<0.01).

Conclusions

Mechanical dysfunction of LA and LAA might play a greater role in pathogenesis of strokes related to AF rather than non-AF strokes.
Right atrio-ventricular strain as a predictor of death in left-sided heart failure
Authors: Vijiiac A E , Scarlatescu A , Petre I , Onciul S , Vatasescu R
Published: October 2024

Background

Right ventricular (RV) strain is an established outcome predictor in heart failure (HF). However, the role of right atrial (RA) strain in the setting of left-sided HF is incompletely understood.

Purpose

We sought to evaluate the RV, RA and combined right atrio-ventricular (RAV) strain using speckle-tracking echocardiography in a cohort of patients with left-sided HF and to assess their prognostic role.

Methods

121 consecutive patients (mean age 59±14 years, 74% men) with HF with reduced ejection fraction (HFrEF) referred to our echocardiography department were prospectively enrolled. The main endpoint was all-cause death. RV strain was measured as the average longitudinal strain of the basal, mid, and apical segments of the RV free wall and was reported as a positive value, thus a lower RV strain reflecting a greater longitudinal dysfunction. RA strain was defined as the maximal longitudinal displacement of the atrial wall at end-systole, corresponding to atrial reservoir function. RAV strain was defined as the sum of RV strain and RA strain.

Results

During a median follow-up of 19±11 months, 26 patients (21%) died. Patients who reached the endpoint had lower left ventricular ejection fraction (LVEF) (21±7% vs. 26±7%, p=0.001), lower tricuspid annular plane systolic excursion (16±3 vs. 18±5, p=0.02) and lower RA strain (13± 10% vs. 18±11%, p=0.03). In univariable Cox regression, RV, RA and RAV strain were all predictors of death: HR=1.05 [95% CI, 1.00-1.11], p=0.045 for RV strain, HR=0.95 [95% CI, 0.91-0.99], p=0.02 for RA strain, HR=0.97 [95% CI, 0.94-0.99], p=0.01 for RAV strain. We constructed a multivariable model with well-established event predictors in HFrEF and one strain index at a time. After adjustment for LVEF, maximal left atrial volume, tricuspid regurgitation severity and pulmonary artery systolic pressure, only RAV strain remained an independent predictor of death (HR=0.97 [95% CI, 0.94-1.00], p=0.04), while RV strain and RA strain did not (p=0.07 for both). LVEF did not emerge as a predictor of death in multivariable regression (p=0.57).

Conclusion

In left-sided HF, RV and RA strain were predictors of death. Combining the longitudinal strain of both right heart chambers might improve risk stratification, since RAV strain remained the only independent predictor of adverse outcome after adjustment for confounders.
Inter-Vendor differences in speckle tracking strain - A ten year follow-up on the Strain Standardization Task Force Inter-Vendor Comparison Study
Authors: Balinisteanu A E , Duchenne J , Puvrez A , Wouters L , Bezy S , Youssef A , De Groef K , Van Langenhoven L , Papangelopoulou K , Cieplucha A , Cattapan I , Tostes P , Vinereanu D , Voigt J U
Published: October 2024

Background

Global longitudinal strain (GLS) derived from two-dimensional speckle-tracking echocardiography is feasible and accurate. Nonetheless, in 2013, the Inter-Vendor Comparison Study showed significant differences of measurement results among vendors. In order to make tracking-based strain imaging a clinically accepted and useful parameter, it is of outmost importance to have interchangeable and accurate measurement results from all vendors.

Purpose

To investigate if the efforts of the EACVI/ASE/Industry Task Force to Standardize Deformation Imaging have led to a reduction of inter-vendor differences during the past ten years.

Methods

In an unique setting, in one single room, 372 echocardiographic examinations were performed in sixty-two subjects (50 male, age 56.1 ± 16.98) with a wide range of left ventricular (LV) function (ejection fraction from 30% to 64%) using ultrasound systems from six manufacturers. Each subject was scanned consecutively on all machines by the same assigned experienced sonographer. For each subject two image sets of LV apical views were acquired in order to assess reproducibility in a true test-retest setting. We assessed mean GLS (GLSAV) as average peak systolic global strain from the three apical views on five vendor-specific and five vendor-independent software solutions. We measured endocardial and mid-/full-wall GLS. Since there is no gold standard method to measure GLS, we compared GLSAV of each vendor to the average of the GLS values only from vendors that provide tracking software solutions (SWS) for clinical use.

Results

For both endocardial (Figure 1) and mid-/full-wall (Figure 2) GLS measurements from clinical SWS were comparable and within a very narrow range (mean GLS of vendors 17.25 ± 0.3% and 15.36 ± 0.3% respectively). The maximum absolute difference between all SWS was 4.1% and 4.9% strain units for endocardial and mid-/full-wall GLS respectively. GLSAV of each software versus the mean of clinical SWS showed significant correlation for most of the companies (r² >0.8, p<0.001). Test-retest variability of GLS measurements expressed as relative mean error was good and lower than for LV ejection fraction (6.3% on average for mean GLS and 7% for LV ejection fraction, p>0.05).

Conclusions

Our data show a substantial inter-vendor bias in GLS measurements. Nevertheless, in contrast to the situation ten years ago, companies that provide tracking software solutions for clinical use provide now very similar GLS values. In addition, most companies do now allow mid-/full-wall tracking. Our data indicate that the efforts of the strain standardization task force have been fruitful. A continuing effort is needed until all software providers adhere to the task force consensus recommendations.Figure 1Figure 2
Long-term prognostic value of heart rate recovery in patients with left bundle branch block without inducible ischemia and without known coronary artery disease
Authors: Boskovic N , Tomovic S , Dedic S , Viduljevic M , Tesic M , Jovanovic I , Aleksandric S , Antonijevic N , Petrovic O , Banovic M , Nedeljkovic I , Beleslin B , Giga V , Djordjevic-Dikic A
Published: October 2024

Background

Heart rate recovery (HRR) has been shown to predict cardiovascular and all-­cause morbidity and mortality. Left bundle branch block (LBBB) is often associated with significant heart disease and is often the result of underlying coronary artery disease (CAD), myocardial injury, strain or hypertrophy. However, there are insufficient data on the prognostic value of HRR in patients with LBBB without inducible ischemia and without known CAD.

Aim

The aim of this study was to determine the long-term prognostic value of HRR in patients with LBBB without inducible ischemia and without known CAD.

Methods

This retrospective study included 182 patients (64, 35.2% male gender, average age 63 ± 10 years) with LBBB and without known CAD who were referred to the SECHO test for chest pain. All the patients had negative SECHO test according the Bruce protocol. Risk factors for CAD (diabetes, smoking, hypertension, high cholesterol and positive family history of CAD), functional capacity (Metabolic Equivalents - METs) and heart rate recovery (HRR) were recorded in all patients. HRR was calculated as the difference between heart rate at the peak stress and heart rate in the first minute of rest. Slow HRR was defined as ≤18 beats/min. Median follow up of the patients was 102.5 months (IQR 68-146 months) for the occurrence of MACE (all-cause mortality, non-fatal myocardial infarction (MI), coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI)).

Results

Overall, 16pts (8.8%) had slow HRR. During the follow-up period 34 out of 182 patients (18.7%) had an adverse event (16 deaths, 10 non-fatal MI, 1 CABG and 7 PCI). Using the Cox regression analysis, univariate predictors of MACE were age (B=0.050, HR 1.051 [95% CI 1.011-1.093], p=0.012), hypertension (B=-1.219, HR 3.385 [95% CI 1.071-10.699], p=0.038), MET (B=-0.183, HR 0.833 [95% CI 0.706-0.982], p=0.030), diabetes (B=0.981, HR 2.667 [95% CI 1.267-5.612], p=0.010) and slow HRR (B=1.171, HR 3.225 [95% CI 1.307-7.959], p=0.011). However, in the multivariate analysis only slow HRR remained the independent predictor of MACE (B=0.974, HR 2.648 [95% CI 0.980-7.151], p=0.048). Using the Kaplan-Meier survival curve we see that the patients with slow HRR had much shorter event-free time compared to the patients with normal HRR (106.9 ± 14.9 months vs 157.9 ± 24 months, Log Rank 7.227, p=0.007) (Figure 1.).

Conclusion

Slow HRR is an independent long-term predictor of adverse events in patients with left bundle branch block without inducible ischemia and without known coronary artery disease.Kaplan-Meier survival curve for the MACE
Comparative analysis of the 2016 diastolic guidelines and left atrial stiffness in predicting exercise tolerance and cardiac events
Authors: Noh S A , Park J S , Choi H M , Hwang I C , Yoon Y E , Cho G Y
Published: October 2024

Background

While the 2016 ASE/EACVI guideline for diastolic dysfunction is a robust tool for prognostication, their complexity and 20% rate of indeterminate limit their routine clinical practice.

Purpose

Left atrial (LA) stiffness, calculated as the E/e' ratio divided by LA strain, provides a simpler measure that indirectly reflects LA pressure. This study aims to evaluate whether LA stiffness can be better than the 2016 guidelines in predicting poor exercise tolerance and cardiac events (cardiac death or heart failure hospitalization) in patients with dyspnea.

Methods

In this retrospective single-center cohort study, 404 patients who underwent echocardiography and cardiopulmonary exercise test simultaneously were reviewed. Poor exercise tolerance was defined by a peak oxygen uptake (VO2) of <14 ml/kg/min or a minute ventilation-carbon dioxide production (VE/VCO2) slope of ≥ 40. The predictive abilities of LA stiffness for peak VO2, VE/VCO2 slope, and cardiac outcomes (cardiac death or heart failure hospitalization) were compared to those of the 2016 guidelines using ROC curve analysis.

Results

The mean left ventricular ejection fraction was 50% (IQR 58.58-66.70). Of the 404 patients (mean age 58.51, male 50.74%), peak VO2 < 14 and VE/VCO2 ≥ 40 were observed in 38 and 24 patients, and cardiac events occurred in 37 patients during median follow up of 85.45 months. ROC analysis showed that LA stiffness had AUC values of 0.697 (95% CI: 0.604-0.789) for peak VO2 < 14, 0.645 (95% CI: 0.529-0.760) for VE/VCO2 slope ≥ 40, and 0.628 (95% CI: 0.541-0.715) for cardiac events. The 2016 guidelines achieved AUCs of 0.685 (95% CI: 0.604-0.766), 0.586 (95% CI: 0.481-0.690), and 0.589 (95% CI: 0.505-0.674). Statistical comparison revealed no significant difference between the predictive capabilities of LA stiffness and the 2016 guidelines (p-values: 0.735, 0.165, and 0.439, respectively). (Figure)

Conclusion

LA stiffness offers comparable diagnostic accuracy to the 2016 ASE/EACVI guidelines in assessing poor exercise tolerance and cardiac events in patients with dyspnea. Given its simplicity and ease of measurement, LA stiffness represents a viable alternative for evaluating diastolic dysfunction.ROC curve
Effects of short-term exposure to high altitude on cardiac function
Authors: Xu Y U N , Wang Y I , Wang S , Yin L
Published: October 2024

Background

What effect does short-term high altitude exposure have on heart function? Can people exercise in the highlands? what changes occur in heart function during exercise in highland areas? This study will explore these topics.

Objectives

To investigate the difference of heart function between people at sea level and at high altitude, and to study the changes of short time exercise on heart function at high altitude.

Methods

36 healthy subjects were recruited to go to high altitude area after underwent exercise echocardiography on a supine bicycle at sea level. They ascended to 3600m within 24 hours by bus.Another exercise echocardiography was performed on the day of arrival.Heart rate (HR), blood pressure (BP) and blood oxygen saturation (SaO2) were monitored in real time during both examinations. Parameters such as left ventricular ejection fraction, E/ E 'and mean pulmonary artery pressure (mPAP) after rest and exercise were calculated.ΔmPAP /CO was calculated by (mean mPAP at peak -mean mPAP at rest )/(mean CO at peak-mean CO at rest).

Results

At peak exercise,SaO2,TRV,RVD2,SPAP,mPAP,PVR, ePLAR,RVAS,ΔMpap/CO were much higher at high altitude levels. (P < 0.001); E,A,FAC,ΔS were significantly lower than that of the sea leval; at rest, HR,TRV,sPAP,mPAP ,PVR were much higher at high altitude levels than at sea leval(P < 0.001)，SaO2,RVOT ACT, were significantly lower than that of the sea leval(P < 0.001).

Conclusions

When healthy people are in high altitude environment, the heart function changes obviously. Supine bicycle exercise stress echocardiography can well monitor the heart function changes and provide quantitative data, providing new technical methods for future related research.
Noninvasive identification of ANOCA endotypes by stepwise, multi-stress, multi-marker stress echocardiography
Authors: Dedic S , Boskovic N , Tesic M , Ciampi Q , Jovanovic I , Giga V , Nedeljkovic I , Cortigiani L , Picano E , Djordjevic Dikic A
Published: October 2024

Background

Angina with non-obstructive coronary artery disease (ANOCA) is increasingly recognized in clinical practice, but effective therapy is difficult due to the heterogenity of pathophysiological substrates: organic coronary microvascular dysfunction (CMD), functional (vasospastic) CMD, epicardial artery vasospasm, non-cardiac chest pain. Current guidelines recommend invasive coronary function testing with the inherent cost of catheterization time, radiation exposure, iodinated contrast effects and risks of invasive procedures.

Objective

To evaluate the feasibility of a step-wise, multi-marker, multi-stress assessment of ANOCA patients by stress echocardiography (SE).

Methods

In a prospective study design, we enrolled 54 ANOCA patients (age =54±14 years, 14 men, 25 %), without significant coronary artery disease (CAD) on invasive or noninvasive angiography. In all patients hyperventilation (HYPER) test (30 deep breaths/min for 5 min) was performed, followed by semi-supine exercise (EX) if negative. All patients underwent adenosine (ADO) test with coronary flow velocity reserve (CFVR) measurement in the mid-distal left anterior descending artery (LAD). Positivity criteria were a coronary flow velocity (CFV) decrease during HYPER despite the increase in the double product (DP) indicating functional CMD i.e. vasoconstriction); the presence of inducible regional wall motion abnormality (RWMA) with HYPER-EX (microvascular/epicardial spasm), and CFVR ≤2.0 with ADO hyperemia (organic CMD).

Results

Fifty one pts (94%) had normal increase in CFV at ADO: CFV rest 0.264±0.078 vs ADO 0.608±0.133, p<0.001, while 3pts (5%) showed decrease in CFV at ADO suggesting organic CMD. Double product (DP) increased during HYPER (rest 10061 ±2406 vs. HYPER 13580 ±3356, p<0.001). Twenty-nine pts (53%) showed a paradoxical vasoconstrictor response during HYPER despite the increase in DP (CFV decreased during HYPER: CFV rest 0.261±0.059 vs HYP 0.216±0.057, p<0.001). With HYPER-EX, RWMA was induced in 15 patients (27%), while 7 patients had also RWMA during HYPER.

Conclusion

In patients with ANOCA, a stepwise multi-marker (CFVR and RWMA) and multi-stress (ADO, HYPER and EX) SE identifies CMD phenotypes and actionable therapeutic targets. According to our results functional vasospastic CMD (paradoxical decrease of CFV with HYPER), is more frequent than organic CMD (reduced CFVR with ADO) in patients with ANOCA. Inducible RWMA with HYPER-EX indicate severe vasoconstrictor response.
Assessment of circulating biomarkers and hemodynamic response during stress to detect early cardiopulmonary complications in systemic sclerosis
Authors: Agoston G , Morvai-Illes B , Jdid Mahmoud S , Hullo D , Szabados T , Varga A , Kovacs L , Bencsik P
Published: October 2024

Background

Systemic sclerosis (SSc) is characterised by persistent immune-inflammatory system activation and excessive extracellular matrix (ECM) accumulation leading to fibrosis. Exercise Doppler Echocardiography (EDE) is a promising method to detect the early changes of fibrosis-related pulmonary and myocardial complications, like elevated left ventricular filling pressure or stress-induced pulmonary hypertension (PH).

Aims

The study aims to assess the linkage between the activity of fibrosis markers and abnormal exercise haemodynamics during stress in patients with SSc.

Methods

A total of 18 patients with SSc were enrolled in the single-centre prospective study (age 54±15,5years, 94,4 % women). SSc patients with resting PH and moderate to severe pulmonary fibrosis were excluded. According to a standardised protocol, all subjects underwent resting and exercise echocardiography on a semi-recumbent cycle ergometer with an incremental (25 watts) workload up to the maximally tolerated workload. Measurements focused on the left ventricular diastolic function (E/e’) and right ventricular haemodynamics (estimated systolic pulmonary pressure: PASP, right ventricular coupling: TAPSE/PASP, pulmonary vascular resistance: PVR). Blood samples were taken immediately before the stress test, and the Matrix Metalloproteinase-9 and 2 (MMP-9, MMP-2) levels were assessed with gelatin zymography method.

Results

During the EDE, PASP from baseline increased significantly (24,6mmHg±11 vs 38±16mmHg, p <0,0001), also PVR (1,2±0,49 vs 1,5±0,15 Wood unit, p<0,001) RV coupling was decreased significantly (1,2±0,68 vs 0,93±0,5, p<0,001). Left ventricular E/e’ was also increased during the stress (8,2±2 vs 10,5±5,1, p<0,05). Enzymatically active MMP-9 level was significantly correlated with RV coupling at rest and stress (p<0,05, r 0,63 at rest and r 0,52 at stress) and negatively correlated with PASP (p<0,05, r:-0,62 at rest and r -0,5 at stress). MMP-2 level only negatively correlated with resting PASP (p<0,05, r:-0,527). The left ventricular parameters did not show any relationship with MMP levels.

Conclusions

The level of circulating MMP-9 predicts haemodynamic behaviour during stress in SSc. MMPs could be a promising marker for detecting early changes in the right ventricle-pulmonary circulation unit.
Prognostic preoperative factors for recurrence of tricuspid regurgitation following annuloplasty: examining the influence of 3d echocardiography
Authors: Verikas D , Krivickiene A , Jakuska P , Siudikas A , Vaskelyte J J , Ereminiene E
Published: October 2024

Introduction

The increasing worry revolves around the reappearance of tricuspid regurgitation (TR) following tricuspid annuloplasty (TA) among individuals dealing with functional tricuspid regurgitation (FTR). Despite TA's efficacy as a treatment, a complete understanding of the echocardiographic elements influencing the recurrence of TR is pivotal. This knowledge holds the potential to guide the development of more robust preventive strategies, aiming to ease the incidence of recurrent TR after TA.

Aim

The aim of this study was to examine the prognostic value of tricuspid valve (TV) and echocardiographic parameters related to both right ventricular (RV) geometry and function. Specifically, our focus is on understanding these relationships in the context of recurrent TR following TA.

Methods

This prospective observational cohort study aimed to investigate determinants of recurrent TR post-surgical TV repair. The focus was on patients with moderate or severe functional TR related to left heart valvular disease, primarily severe mitral regurgitation, excluding those with ischemic heart disease. The study involved 66 participants, assessed preoperatively with 2D and 3D echocardiography, examining RV and right atrial (RA) geometry, functional, and TV parameters. TR severity followed ESC guidelines. Two groups were formed: effective TA group (50 patients) and recurrent TR group (16 patients), defined by mild to moderate TR and significant moderate-severe TR one year post-surgery, respectively. Statistical analysis employed SPSS software, with adjusted univariate logistic regression considering age and gender.

Results

Of the patients, 54% were male, with a mean age of 68±9 years. Echocardiography parameters in Table 1 showed no significant differences in gender, left ventricular, atrial geometrical, functional parameters, or preoperative effective regurgitant TV orifice area between groups (recurrent TR vs. effective TA: 38 [33] mm2 vs. 29 [15] mm2, p=0.117). Univariate logistic regression analysis highlighted RV and RA geometry, along with TV diameter, as predictors for recurrent TR. Notably, 3D TV geometrical parameters had prognostic significance, as confirmed by univariate adjusted logistic regression analysis. Functional RV parameters did not exhibit statistical significance in this analysis.

Conclusion

In conclusion, the recurrence of moderate-severe functional tricuspid regurgitation following tricuspid annuloplasty is linked to the tricuspid annulus size, as well as the geometry of the right atrium and right ventricle before surgery. Notably, no correlation was identified between the recurrence of TR and alterations in RV function.
Speeding up echocardiographic examination by automated generation of 2D imaging views from 3D volumetric data using machine learning
Authors: Fan Y , Tam J , Wong K Y , Lee A
Published: October 2024

Background

3D echocardiographic data contain infinite 2D echocardiographic planes generated by multiplanar reconstruction, but the process is labor-intensive and time-consuming. Artificial intelligence (AI) utilizing cutting-edge machine learning techniques may improve the accuracy and efficiency of the process. In the study, we developed and validated an AI software that automatically reconstructs 7 2D views recommended by the American Society of Echocardiography from 3D echocardiographic data.

Method

Convolutional neural network (CNN) architecture utilizing Spatial Configuration Net was used as the machine learning model. We identify a minimum of 3 key feature landmarks on each 2D cross-sectional plane, with the 3D coordinates representing 2D cross-sectional planes accordingly. Subsequently, these landmarks are accurately labeled within a 3D space. 31 landmarks were identified across 7 2D cross-sectional planes and a total of 472 3D volume data were labelled. The performance of the model is evaluated by Root Mean Square Error (RMSE) of the predicted landmark coordinates.

Results

The mean RMSE over 31 predicted landmarks evaluated in testing is 2.70% for the input 3D volume dimensions. The average time used to generate the 7 2D imaging views was 19.91±3.19 seconds (figure).

Conclusion

The AI algorithm can efficiently convert 3D echocardiographic data into guideline-recommended 2D images, which shortens the length of echo examination but still preserves the accuracy.AI generation of 2D views from 3D echo
Diastolic dysfunction and survival in patients with preserved or mildly reduced left ventricular ejection fraction
Authors: Chan N , Atherton J J , Hammett C , Stewart P , Mallouhi M , Vollbon W , Prasad S B
Published: October 2024

Background

Left ventricular ejection fraction (LVEF) is relatively indiscriminate for prognosis in patients with preserved or mildly reduced LVEF (>40%) following myocardial infarction (MI).

Aims

This study sought to determine the value of guideline-based assessment of diastolic dysfunction (DD) in predicting all-cause and cardiac mortality in patients with a first-ever MI and LVEF>40%.

Methods

A retrospective single centre study involving 2234 patients with a first-ever MI (STEMI or NSTEMI) with LVEF>40% was performed. Clinical, angiographic, and echocardiographic data were obtained from prospectively maintained institutional databases. Outcomes data were obtained from the state-wide registry. Echocardiography was performed early post-admission for all patients. Significant diastolic dysfunction (DD) was defined as grade 2+3 diastolic dysfunction according to current American Society of Echocardiography/ European Association of Cardiovascular Imaging guidelines.

Results

The mean age of patients was 61.4±12.3 years, 70.7% were males, and 12.1% had 3-vessel disease. The mean LVEF was 55.8±7.2% and 9.1% had significant DD. At a median follow up of 4.5 years, there were 219 deaths (46 cardiac deaths). On Cox proportional hazards multivariable analyses incorporating significant clinical, angiographic, and echocardiographic variables, significant DD was an independent predictor of both all-cause (HR 2.01,95%CI 1.37-2.94, p<0.001) and cardiac (HR 3.97,95%CI 1.98-7.99, p<0.001) mortality.

Conclusions

Significant DD is an independent predictor of all-cause and cardiac mortality following MI in patients with preserved or mildly reduced LVEF and thus effectively re-stratifies prognosis in a subgroup where the LVEF is relatively indiscriminate for survival. The benefit of further investigation and/or treatment in this subgroup needs further study.
Association of renal circulation at acute phase with decongestion level at discharge in patients admitted for acute decompensated heart failure
Authors: Kayama K , Kikuchi S , Sugimoto T , Seo Y
Published: October 2024

Background

In patients admitted with acute decompensated heart failure (ADHF), renal hemodynamics may play an important role in the clinical course during hospitalization based on the close cardio-renal relationship. Superb Microvascular Imaging (SMI), distinguished by its advanced clutter suppression capabilities to reveal microflow details, holds promise for evaluating renal circulation. Consequently, our study aims to explore the association between renal circulation as assessed by SMI and the levels of brain natriuretic peptide (BNP) at discharge as an indicator of decongestion status.

Methods

In a prospective design, 45 ADHF patients were sequentially examined via renal ultrasound with SMI at discharge. The vascular index (VI) by SMI was calculated as the percentage of blood flow signal area in the region of interest. Then, the intra-renal perfusion index (IRPI) as an index of cyclic variation in VI, was calculated as the maximum VI minus the minimum VI within one cardiac cycle in the ROI divided by the Max.VI (Figure A).

Results

The values of IRPI were as follows: at 12h, 0.70±0.04; at 48h, 0.58±0.05; at 1W, 0.50±0.04; and at discharge, 0.61±0.04. The IRPI measured at 48h showed a stronger correlation with BNP at discharge (r = 0.57, p<0.001) than those at the other three points (Figure B). Patients with higher log BNP at discharge (> 2.31: determined by the median value) had significantly higher IRPI and age, and lower hemoglobin levels at 48h, however, there were no significant differences in estimated glomerular filtration rate, ejection fraction, or systolic pulmonary artery pressure at 48h. The area under the curve of IRPI at 48h for higher log BNP at discharge > 2.31 at discharge was 0.746 (sensitivity 100%, specificity 48%).

Conclusion

Early assessment of renal circulation by SMI around 48 hours after ADHF admission may predict congestion resolution at discharge. This underscores the potential utility of SMI in guiding more aggressive decongestive treatment strategies earlier in ADHF.
Empowering patients with heart failure: a digital health solution improved self-care and metabolic outcomes in a randomized controlled trial
Authors: Arnar D O , Gudmundsson E F , Dobies B , Sigurdardottir S , Hrafnkelsdottir T J , Broddadottir H , Gudlaugsdottir G J , Laxdal B , Asgeirsdottir L , Kaernested B , Bragadottir H B , Isberg A , Helgadottir H , Sigurdsson A F , Oddsson S J
Published: October 2024

Background/Introduction

Heart failure is a common cause of morbidity and mortality and poses a significant burden on patients and healthcare providers.

Purpose

The aim of the study was to evaluate whether a digital health program improves quality of life and clinical outcomes for patients with heart failure.

Methods

A single-center, randomized controlled trial (RCT) was conducted with patients receiving standard of care (SoC) at a heart failure outpatient clinic. Patients were randomized (1:1) to receive either SoC alone or SoC with an additional six-month digital health program. The program consisted of remote patient monitoring (RPM) with symptom tracking, disease-specific education, and lifestyle coaching, designed to empower patients with heart failure. After the main program concluded, a six-month maintenance program was initiated, consisting of recurrent educational materials, with reduced coaching- and RPM frequency. The primary endpoint was the 12-item Kansas City Cardiomyopathy Questionnaire (KCCQ-12) at six months. Secondary endpoints included the European Heart Failure Self-care Behaviour Scale-9 (EHFScB-9), 6-question heart failure knowledge questionnaire, and metabolic outcomes. Here we report on the Intention-to-Treat (ITT) population analysis for the primary and significant secondary endpoints at six and 12 months.

Results

The ITT included 175 participants, 86 in the program group and 89 in the control. Program group: mean age (SD) 64.7 (13.2), 66.3% male, 87.2% with NYHA stages I-II. Control group: mean age (SD) 66.2 (11.1) years, 69.7% male, 87.6% with NYHA stages I-II. Median compliance with RPM was 93% and in-app retention was 80% at six months. Results for primary and secondary endpoints are presented in Table 1 and Figure 1. No statistical difference was observed in the KCCQ score between groups at six or 12 months. The program group had statistically significant improvements in EHFScB-9 score at six and 12 months and in heart failure knowledge at 12 months compared to the control group. Metabolic outcomes: a significant difference in glucose levels was also observed between groups at six months, and in HbA1c and triglycerides levels at 12 months.

Conclusions

The difference between groups in the primary endpoint of heart failure symptoms and quality of life, as measured by the KCCQ-12, was not statistically significant. However, significant differences were observed in self-care behaviour and heart failure knowledge, as well as metabolic outcomes at six and 12 months, when compared with standard care alone. These findings, along with good retention and engagement, indicate the value to patients of digital health interventions in the management of heart failure.
Feasibility and efficacy of acetazolamide in the treatment of acute decompensated heart failure
Authors: Iemura Y
Published: October 2024

Background

The ADOVAR trial showed that the addition of acetazolamide to loop diuretics could be expected to result in more rapid diuresis and shorter hospital stays in patients with acute decompensated heart failure (ADHF). However, tolvaptan and SGLTII inhibitors are often added for patients with ADHF in Japan.

Method

An inception cohort of patients with ADHF admitted between January 2022 and June 2023 was assessed. We studied baseline characteristics and divided the patients into "acetazolamide-use" and "no-use" groups. After three days of admission, the endpoint was the reduction rate of body weight, urine output, and the Congestion Score Index (CSI) improvement rate.

Results

A total of 222 patients were included (73 of the use group and 149 of the no-use group). Baseline characteristics showed the use of catecholamines, PDE III inhibitors, and SGLTII inhibitors were higher in the use group (30.1% vs. 14.8%; P<0.05, 37.0% vs. 8.1%; P<0.05, and 75.3% vs. 38.3%; P<0.05). The reduction rate of body weight, the amount of urine output, and the CSI improvement rate were higher in the use group (6.5% vs. 4.1%; P<0.05, 2745.8ml/day vs. 2004.8ml/day; P<0.05, and 27.8% vs. 19.2%; P<0.05). A hierarchical multiple regression analysis showed the use of acetazolamide and SGLT II inhibitors were the factors that contributed to the reduction of body weight, the amount of urine output, and the improvement of the CSI (P<0.05).

Conclusion

The addition of acetazolamide to daily medical therapy in patients with ADHF in Japan resulted in a greater incidence of successful decongestion.
Heart failure treatment in the last years of life - a nationwide study of 364,000 individuals
Authors: Lindholm D , Gustafsson S , Cars T , Sundstrom J
Published: October 2024

Background

Heart failure treatment patterns towards the end of life have rarely been studied at large scale. Yet, this is important to assess, since heart failure is a chronic condition with patients on treatment for potentially many years.

Purpose

To investigate treatment patterns in the last years of life in patients with heart failure.

Methods

In a register-based study covering the whole Swedish population between 2007 and 2020, we investigated treatment patterns in the last years of life in 364,480 individuals who died with heart failure. We combined binomial models (to estimate proportion on treatment at death) and Poisson models (to estimate discontinuation rate), to estimate the proportion on each heart failure treatment up to 5 years prior to death, using penalized splines to allow for non-linearities. We also assessed comorbidity patterns over time.

Results

All heart failure treatments saw a gradual discontinuation closer to death, but the discontinuation rate of beta blockers decreased over time, resulting in an increasing proportion of patients on treatment at the time of death (Fig). Also, the pattern of comorbidities changed over time, with an increase in e.g., hypertension and atrial fibrillation, but a decline in ischemic heart disease (63% in 2007 gradually declining to 54% in 2020).

Conclusions

In this nationwide study, we observed a changing pattern of medical treatment of heart failure during the last years of life, most notably with an increasing use of beta blockers. Comorbidities and the shares of heart failure etiologies also changed over time, with an increase in several conditions but a decline in ischemic heart disease. Taken together, this may have important implications for planning and optimizing care for these patients.
The effects of angiotensin receptor-neprilysin inhibitors on clinical outcomes in heart failure with mildly reduced or preserved ejection fraction: real-world evidence from the CCA Database-HF Center
Authors: Xie Z , Cui X , Xu Y , Wang Y , Dong Y , Liao Y , Li W , Li X , Yang J , Zhou J , Ge J
Published: October 2024

Background

Recent clinical trials have demonstrated the potential efficacy and safety of angiotensin receptor-neprilysin inhibitors (ARNI) in patients with heart failure (HF) with mildly reduced or preserved ejection fraction. Nevertheless, the generalizability of these findings in real-world clinical settings remains to be determined. We aimed to compare the real-world effectiveness of ARNI versus angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEI/ARB)on clinical outcomes in HF patients with mildly reduced or preserved ejection fraction.

Methods

Patient-level data was derived from the China Cardiovascular Association Database-HF Center Registry. We included exclusively a subpopulation of HF patients with left ventricular ejection fraction (LVEF) >40% and comorbid with hypertension. Patients prescripted with ARNI at discharge and sustaining to ARNI therapy during follow-up were categorized as the ARNI group, while those maintaining the usage of ACEI/ARB after discharge were designated as the ACEI/ARB group. In complete cases, the primary endpoint of all-cause mortality at one year was assessed by the 1:1 propensity score matching (PSM) method.

Results

In all HF patients with LVEF >40% comorbid with hypertension, the usage of ARNI has increased from 0.9% in 2017 to 37.2% in 2021. A total of 3348 patients in the ARNI group and 7688 patients in the ACEI/ARB group were identified for comparative effectiveness. After 1:1 PSM, 5482 patients were included in the primary analysis, with 2741 patients in each treatment arm. The proportion of patients receiving higher dosages of ARNI (200mg/d and 400mg/d) was 20.9%, 26.6%, 29.2%, and 30.3% at discharge, 1-month, 3-month, and 1-year, respectively. Over the 1-year follow-up, ARNI was associated with a 20% relative reduction in all-cause death compared to the ACEI/ARB therapy (10.5% vs. 12.9%, adjusted hazard ratio [HR], 0.80 [95% CI, 0.69-0.94], P=0.005). The absolute risk difference in all-cause death between ARNI and ACEI/ARB arms was 2.88 per 100 patient-years (incidence rate difference, -2.88 [95% CI, -4.86 to -0.9]). Cardiovascular death also tended to decrease in the ARNI group but with missed statistical significance (4.5% vs. 4.9%, adjusted HR, 0.89 [95% CI, 0.70-1.14], P=0.373). Treatment benefits were more significant in those with LVEF between 40-50% (adjusted HR, 0.62 [95% CI, 0.48-0.79]), 50-60% (adjusted HR, 0.85 [95% CI, 0.68-1.06]), but not observed in HF patients with LVEF>60% (adjusted HR, 1.80 [95% CI, 1.08-2.98]; Pinteraction<0.001).

Conclusion

In real-world clinical settings, treatment with ARNI was associated with a significant relative risk reduction in all-cause mortality compared with ACEI/ARB in HF patients with mildly reduced or preserved LVEF. The cardiovascular benefit was concentrated in patients with LVEF ≤60%.